

**DRUG DISCOVERY TODAY****Editorial**

**Editor:** Steve Carney  
**Content Development Manager:** Pien van Spijker  
**Journal Manager:** Bharathi Sims  
**Publisher:** Fernanda Ogochi  
**Editorial Enquiries:**  
*Drug Discovery Today*  
 Elsevier  
 125 London Wall, London, EC2Y 5AS, UK  
 Tel: +44 (0) 20 8439 5525  
 Fax: +44 (0)1865 853067  
 Email: ddt@drugdiscoverytoday.com

**ADVISORY EDITORIAL BOARD**

**Jürgen Bajorath** University of Bonn, Germany  
**Walter Blackstock** Experimental Therapeutics Centre, Singapore  
**David Brayden** University College Dublin, Ireland  
**Paul Caron** Integrated Profiling, USA  
**David Cavalla** Numedix Ltd., UK  
**David Clark** Argenta Discovery, UK  
**Dalia Cohen** ALN Associates, USA  
**Donald Daley** Argenta Discovery, UK  
**Sean Ekins** Collaborations in Chemistry, USA  
**Hans-Peter Fischer** GeneData, Switzerland  
**Peter Ghazal** University of Edinburgh, UK  
**Christopher M. Hill** Merck, USA  
**Nick Hird** Takeda Chemical Industries, Japan  
**Enoch Huang** Pfizer, USA  
**Thomas Joos** University of Tuebingen, Germany  
**Vincent H.L. Lee** Chinese University of Hong Kong, China  
**David Lewin** Yale University, USA  
**Christopher A. Lipinski** Melior Discovery, USA  
**Lorenz Mayr** AstraZeneca, UK  
**Nick Meanwell** Bristol-Myers Squibb, USA  
**BK Muralidhara** Acceleron Pharma Inc, USA  
**Mark Murcko** Disruptive Biomedical, LLC, USA  
**Fajun Nan** Shanghai Institute of Materia Medica, China  
**Pradeep Nathan** Experimental Medicine, GSK and University of Cambridge  
**Gitte Neubauer** Cellzome, Germany  
**Eric Neumann** Clinical Semantics Group Consulting, USA  
**Tim Peakman** UK Biobank, UK  
**Norton Peet** Microbiotix, Inc., USA  
**Manuel Peitsch** Swiss Institute of Bioinformatics, Switzerland  
**Kurt Rasmussen** Eli Lilly and Co. Ltd., USA  
**Janice Reichert** Reichert Biotechnology Consulting LLC, MA, USA  
**John Reidhaar-Olson** Albert Einstein College of Medicine, New York, USA  
**Mike Romanos** Crescendo Biologics, Cambridge, UK  
**Raymond C. Rowe** Intelligensys, UK  
**Andreas Russ** University of Oxford, UK  
**Esther Schmid** EFS Strategy and Business Consulting, UK  
**Jonathan Sheldon** Translational Medicine, Oracle, UK  
**Michael Snyder** Stanford University, USA  
**Susie Stephens** Johnson & Johnson, USA  
**Robert Strausberg** Ludwig Institute for Cancer Research, New York, USA  
**Yuichi Sugiyama** University of Tokyo, Japan  
**David Szymkowski** Xencor, USA  
**Nick Terrett** Ensemble Discovery, USA  
**Vladimir Torchilin** Northeastern University, Boston, USA  
**Mark Whittaker** Evotec OAI, UK  
**Hans Winkler** Janssen Pharmaceutica, Belgium  
**Limsoon Wong** National University of Singapore  
**X.F. Steven Zheng** Robert Wood Johnson Medical School, USA

# DRUG DISCOVERY TODAY

## 1575 Poloxamer-based *in situ* gelling thermoresponsive systems for ocular drug delivery applications

Karim A. Soliman, K Ullah, A. Shah, David S. Jones and Thakur R.R. Singh

**INFORMATICS**

## 1587 Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development

Hovhannes J. Gukasyan, Shumet Hailu, Thomas K. Karami and Richard Graham

**GENE TO SCREEN**

## 1598 Targeting P2X7 receptors as a means for treating retinal disease

Erica L. Fletcher, Anna Y. Wang, Andrew I. Jobling, Matthew V. Rutar, Ursula Greferath, Ben Gu and Kirstan A. Vessey

## 1606 Causative glaucoma treatment: promising targets and delivery systems

Raphael Mietzner and Miriam Breunig

## 1614 Nitric oxide: a drug target for glaucoma revisited

Gerhard Garhöfer and Leopold Schmetterer

**POST SCREEN**

## 1621 Modified cells as potential ocular drug delivery systems

Tatiana Tennikova and Arto Urtti

## 1627 Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy

Odunayo O. Mugisho, Colin R. Green, Jie Zhang, Monica L. Acosta and Ilva D. Rupenthal

## 1637 Drug delivery to retinal photoreceptors

Erico Himawan, Per Ekström, Matej Buzgo, Pieter Gaillard, Einar Stefánsson, Valeria Marigo, Thorsteinn Loftsson and François Paquet-Durand

## 1644 Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases

Alicia Arranz-Romera, Sergio Esteban-Pérez, David Garcia-Herranz, Alba Aragón-Navas, Irene Bravo-Osuna and Rocío Herrero-Vanrell

## 1654 Targeting drug delivery within the suprachoroidal space

Jae Hwan Jung, J. Jeremy Chae and Mark R. Prausnitz

## 1660 Recent developments in liposomal drug delivery systems for the treatment of retinal diseases

Andrew J. Urquhart and Anne Z. Eriksen

## 1669 Retinal cell regeneration using tissue engineered polymeric scaffolds

Maria Abedin Zadeh, Mouhamad Khoder, Ali A. Al-Kinani, Husam M. Younes and Raid G. Alany

## 1679 Challenges and opportunities for drug delivery to the posterior of the eye

Fernando J. Cabrera, Daniel C. Wang, Kartik Reddy, Ghanashyam Acharya and Crystal S. Shin

## 1685 Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives

Thierry Bordet and Francine Behar-Cohen

## 1694 Recent advances in intraocular sustained-release drug delivery devices

Yiqi Cao, Karen E. Samy, Daniel A. Bernards and Tejal A. Desai

**FORTHCOMING ARTICLES:**

### Unbiased data analytic strategies to improve biomarker discovery in precision medicine.

By Saifur R. Khan, Yousef Manialawy, Michael B. Wheeler and Brian J. Cox

### Data science tools and applications on the way to Pharma 4.0.

By Valentin Steinwandter, Daniel Borchert and Christoph Herwig

### Physicians in the pharmaceutical industry: their roles, motivations, and perspectives.

By Hussein Sweiti, Frank Wiegand, Christoph Bug, Martin Vogel, Frederic Lavie, Ivo Winiger-Candolfi and Maximilian Schuier

### Skin metabolism Phase I and Phase II enzymes in native and reconstructed human skin: a short review.

By Siamaque Kazem, Emma Charlotte Linssen and Susan Gibbs